Difference between revisions of "Part:BBa K3497998:Design"

(→‎References)
(→‎Design Notes)
 
(3 intermediate revisions by the same user not shown)
Line 9: Line 9:
 
design considerations
 
design considerations
  
−
 
+
test
  
 
===Source===
 
===Source===
  
−
source of this part.
+
GenBank: JN695597.1
  
 
===References===
 
===References===

Latest revision as of 01:40, 12 March 2021


Chironex fleckeri toxin A precursor mRNA, complete cds


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 682
    Illegal PstI site found at 659
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 682
    Illegal NheI site found at 529
    Illegal PstI site found at 659
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 682
    Illegal BglII site found at 1075
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 682
    Illegal PstI site found at 659
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 682
    Illegal PstI site found at 659
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI.rc site found at 166


Design Notes

design considerations

test

Source

GenBank: JN695597.1

References

  1. Balakumar P, Jagadeesh GJCs. A century old renin–angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. 2014;26(10):2147-2160.
  2. Shrikrishna D, Astin R, Kemp PR, Hopkinson NSJCs. Renin–angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. 2012;123(8):487-498.
  3. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. 2002;166(5):646-650.
  4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. 2000;87(5):e1-e9.
  5. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. 2005;436(7047):112-116.
  6. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. 2005;11(8):875-879.
  7. Meng Y, Yu C-H, Li W, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-κB pathway. 2014;50(4):723-736.
  8. Guang C, Phillips RD, Jiang B, Milani FJAocd. Three key proteases–angiotensin-I-converting enzyme (ACE), ACE2 and renin–within and beyond the renin-angiotensin system. 2012;105(6-7):373-385.
  9. Deng W, Deng Y, Deng J, Wang D-X, Zhang TJIjoc, pathology e. Losartan attenuated lipopolysaccharide-induced lung injury by suppression of lectin-like oxidized low-density lipoprotein receptor-1. 2015;8(12):15670.
  10. Zambelli V, Bellani G, Borsa R, et al. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. 2015;3(1):1-17.
  11. Treml B, Neu N, Kleinsasser A, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. 2010;38(2):596-601.
  12. Lei C, Qian K, Li T, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. 2020;11(1):1-5.
  13. Bernstein KE, Khan Z, Giani JF, Cao D-Y, Bernstein EA, Shen XZJNRN. Angiotensin-converting enzyme in innate and adaptive immunity. 2018;14(5):325.